Threshold Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Threshold Pharmaceuticals, Inc.
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
Eton Pharmaceuticals gets untitled letter for promotion of its Alkindi Sprinkle hydrocortisone granules for treatment of pediatric adrenal insufficiency. The agency sent two letters last year objecting to sponsored links after a decade pause.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.